trastuzumab deruxtecan

Wed, 24 Jul 2024 14:31:49 -0400

As monotherapy, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1)